期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Sustiva和Truvada联合治疗HIV
1
作者 张燕 《国外药讯》 2005年第6期26-26,共1页
BMS公司和Gilead Sciences公司在美国合作,以开发各自的抗艾滋病药物Sustiva(efavirenz)(Ⅰ)和Truvada(emtricitabine+tenofovir disoproxilfumarate)(Ⅱ)的固定剂量复合制剂治疗HIV。
关键词 Sustiva truvada 联合治疗 HIV 抗艾滋病药物 固定剂量
下载PDF
美国FDA咨询委员会发布关于Truvada的建议
2
《中国新药杂志》 CAS CSCD 北大核心 2012年第12期1421-1421,共1页
美国FDA的抗病毒药物咨询委员会日前经投票决定支持批准Gilead Sciences公司的Truvada(tenofovir disoproxil fumarate/emtricitabine)用于降低未被感染成人感染HIV-1的风险。经过投票,FDA咨询委员会最终以19赞成、3票反对的投票结... 美国FDA的抗病毒药物咨询委员会日前经投票决定支持批准Gilead Sciences公司的Truvada(tenofovir disoproxil fumarate/emtricitabine)用于降低未被感染成人感染HIV-1的风险。经过投票,FDA咨询委员会最终以19赞成、3票反对的投票结果支持男同性恋者接触前使用本品以预防艾滋病(PrEP)。 展开更多
关键词 美国FDA咨询委员会 truvada 抗病毒药物 临床试验
原文传递
预防HIV感染药物Truvada
3
《药学进展》 CAS 2012年第9期434-434,共1页
2012年7月16日美国FDA批准Truvada用于HIV感染高危人群“接触HIV前的预防性治疗”(PrEP),从而使该药成为首个预防HIV感染药物。本品为Gilead公司开发的低剂量抗逆转录病毒药恩曲他滨/替诺福韦复方片剂,先前已获准用于治疗HIV感染者。
关键词 truvada 抗逆转录病毒药 HIV感染 预防性治疗
原文传递
美国FDA最新批准上市的治疗AIDS药物 被引量:2
4
作者 赵思太 臧恒昌 赵桂森 《中国新药杂志》 CAS CSCD 北大核心 2005年第3期373-374,共2页
艾滋病是由人免疫缺陷病毒(Human Immunodeficiency Virus,HIV)引起的全身免疫缺陷性疾病,患者免疫功能低下,故该疾病被称为获得性免疫缺陷综合征(Acquired Immunodeficiency Syndrome,AIDS).截至2004年8月,美国FDA共批准上市26种药物用... 艾滋病是由人免疫缺陷病毒(Human Immunodeficiency Virus,HIV)引起的全身免疫缺陷性疾病,患者免疫功能低下,故该疾病被称为获得性免疫缺陷综合征(Acquired Immunodeficiency Syndrome,AIDS).截至2004年8月,美国FDA共批准上市26种药物用于HIV感染治疗[1],现将2003-2004年8月批准的6种抗HIV药物整理如下,供我国有关药物研究、开发、管理等方面参考. 展开更多
关键词 HIV Fuzeon Reyataz Emtriva truvada Lexiva Epzicom
下载PDF
Stability Indicating RP-UPLC Method for Assay of Emtricitabine and Tenofovir Disoproxil Fumarate in Bulk and Dosage Forms
5
作者 Bommakanti Valli Purnima Tummala Vijaya Bhaskara Reddy +2 位作者 Yadlapalli Srinivas Rao Golkonda Ramu Dittakavi Ramachandran 《American Journal of Analytical Chemistry》 2015年第10期807-821,共15页
A simple, sensitive and rapid stability indicating reverse phase ultra performance liquid chromatography (RP-UPLC) method was developed and validated for the determination of Emtricitabine (EMT) and Tenofovir disoprox... A simple, sensitive and rapid stability indicating reverse phase ultra performance liquid chromatography (RP-UPLC) method was developed and validated for the determination of Emtricitabine (EMT) and Tenofovir disoproxil fumarate (TDF) in pure and tablet dosage forms. The chromatographic separation was achieved by using Waters (Alliance) UPLC system equipped with auto-sampler and photo diode array detector. A volume of 5 μL of standard or test was injected into the column and the components were separated by using the mixture of 0.68% potassium dihydrogen orthophosphate buffer of pH = 6 and methanol in the ratio 45:55 v/v as mobile phase at a flow rate of 1.2 mL/min through BEH C18 (100 mm × 2.1, 1.8 μm) at ambient temperature and were detected at a wavelength of 261 nm. System suitable parameters such as plate count and tailing factor for EMT and TDF were found to be 2427 & 3685, 1.16 & 1.23 respectively, and resolution between EMT and TDF peaks was found to be 3.12. The chromatographic parameters like retention time, peak area and peak height of EMT and TDF were found to be 0.684 & 0.930, 694,200 & 8,778,000 and 272,881 & 3685 respectively. Percent of assay of EMT and TDF in bulk and dosage forms was determined and found to be 101.48 and 103.22 respectively. Study of degradation was examined and found that the drugs were stable under degradation conditions. The present method was developed keeping the principles of green chemistry by using eco-friendly solvent methanol in mobile phase. The developed method was found to be simple, rapid and applied for the analysis of Truvada;therefore the proposed method is recommended for the analysis of EMT and TDF in pure and tablet dosage forms in any quality control laboratories. 展开更多
关键词 truvada EMTRICITABINE TENOFOVIR DF VALIDATION ASSAY
下载PDF
Milestones in the discovery of antiviral agents:nucleosides and nucleotides
6
作者 Erik de Clercq 《Acta Pharmaceutica Sinica B》 SCIE CAS 2012年第6期535-548,共14页
In this review article,a number of milestones in the antiviral research field on nucleosides and nucleotides are reviewed in which the author played a significant part,especially in the initial stages of their develop... In this review article,a number of milestones in the antiviral research field on nucleosides and nucleotides are reviewed in which the author played a significant part,especially in the initial stages of their development.Highlighted are the amino acyl esters of acyclovir,particularly valacyclovir(VACV),brivudin(BVDU)and the valine ester of Cf1743(FV-100),the.2′,3′-dideoxynucleosides(nucleoside reverse transcri ptase inhibitors,NRTIs),the acyclic nucleoside phosphonates(S)-HPMPA,(S)-HPMPC(cidofovir)and alkoxyalkyl esters thereof(HDP-,ODE-CDV),adefovir and adefovir dipivoxil,tenofovir and tenofovir disoproxil fumarate(TDF),combinations containing TDF and emtricitabine,i.e.,Truvada■,Atripla■,Complera■/Eviplera■ and the Quad pill,and the phosphonoamidate derivatives GS-7340,GS-9131,GS-9191 and GS-9219. 展开更多
关键词 VALACYCLOVIR Brivudin FV-100 EMTRICITABINE (S)-HPMPA (S)-HPMPC CIDOFOVIR ADEFOVIR TENOFOVIR truvadas■ Phosphonoamidate
原文传递
An Odyssey in antiviral drug development—50 years at the Rega Institute:1964–2014 被引量:3
7
作者 Erik De Clercq 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2015年第6期520-543,共24页
I.How it started I entered the Rega Institute for Medical Research in August 1964,as a medical student,to start working under the guidance of Prof.Piet De Somer,then professor of microbiology at the Leuven School of M... I.How it started I entered the Rega Institute for Medical Research in August 1964,as a medical student,to start working under the guidance of Prof.Piet De Somer,then professor of microbiology at the Leuven School of Medicine.When I graduated 展开更多
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部